Nitric oxide-releasing aspirin but not conventional aspirin improves healing of experimental colitis

Table 2 Evaluation of related markers in trinitrobenzenesulfonic acid rats treated ig with non-selective and selective cyclooxygenase-1 and cyclooxygenase-2 inhibitors or nitric oxide-aspirin throughout the period of 10 d in 6-10 rats per group (mean ± SE)

Treatment	Weight (mg)	MPO (ng/mL)	IL1-β(pg/mL)	TNF-α(pg/mL)
Vehicle	1150 ± 23.1	51 ± 8.1	42 ± 3.4	4.8 ± 0.6
ASA (80 mg/kg)	1580 ± 41.4a	78 ± 9.3a	65 ± 5.1a	8.5 ± 0.95a
Indomethacin (5 mg/kg)	1450 ± 45.8a	65 ± 5.2a	58 ± 4.1a	7.8 ± 0.62a
SC-560 (5 mg/kg)	1310 ± 32.4a	52 ± 6.8a	53 ± 3.9a	7.5 ± 0.46a
Celecoxib (10 mg/kg)	1082 ± 14.9c	44 ± 4.3c	36 ± 2.2c	3.8 ± 0.33c
NO-ASA (80 mg/kg)	710 ± 12.3e	35 ± 3.2e	18 ± 1.5e	2.4 ± 0.21e

MPO: Myeloperoxidase; TNF: Tumor necrosis factor; ASA: Aspirin; SC-560: 5-​(4-​chlorophenyl)-​1-​(4-​methoxyphenyl)-​3-​(trifluoromethyl)-​1H-​pyrazole; NO: Nitric oxide.

^aP < 0.05 vs vehicle;

^cP < 0.05 vs vehicle, ASA, indomethacin or SC-560 groups;

^eP < 0.05 vs groups treated with non-selective and selective COX-1 or COX-2 inhibitors.